Ftse Mib
37.917,45
0,02%
DAX
22.486,75
-0,55%
S&P 500
6.117,86
0,05%
NASDAQ
19.975,94
0,15%
Bitcoin
96.768,75
0,16%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Intesity Therapeutics Inc (INTS) Intesity Therapeutics Inc (INTS) Notizie

Intesity Therapeutics Inc

INTS
2,29
0,12 (5,53%)
Ultimo aggiornamento: 16:26:54
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
28/1/202514:00PRNUSDrug Monitoring Committee Authorizes Continuation of..
10/1/202514:00PRNUSIntensity Therapeutics Provides Business Update Highlighting..
30/12/202423:21EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
20/12/202422:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/12/202422:00EDGAR2Form S-1 - General form for registration of securities under..
12/12/202414:00PRNUSIntensity Therapeutics, Inc. and The Swiss Group for..
22/11/202412:15EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
22/11/202403:43EDGAR2Form 8-K - Current report
21/11/202414:00PRNUSIntensity Therapeutics, Inc. Announces Pricing of $3 Million..
20/11/202423:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/11/202414:00PRNUSIntensity Therapeutics Presents INT230-6 Phase 1/2 Data in..
13/11/202422:10EDGAR2Form 8-K - Current report
13/11/202422:06PRNUSIntensity Therapeutics Reports Third Quarter 2024 Financial..
13/11/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202414:01PRNUSIntensity Therapeutics Selected for Oral Podium Presentation..
31/10/202414:00PRNUSIntensity Therapeutics, Inc. and The Swiss Group for..
23/10/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/10/202422:20EDGAR2Form 8-K - Current report
04/9/202414:00PRNUSIntensity Therapeutics to Present at the H.C. Wainwright..
08/8/202422:22EDGAR2Form 8-K - Current report
08/8/202422:19PRNUSIntensity Therapeutics Reports Second Quarter 2024 Financial..
08/8/202422:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
17/7/202422:01EDGAR2Form 8-K - Current report
09/7/202414:01PRNUSIntensity Therapeutics, Inc. Announces First Patient Dosed..
07/6/202423:29EDGAR2Form SC 13G - Statement of acquisition of beneficial..
07/6/202413:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:07EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
04/6/202422:05EDGAR2Form DEF 14A - Other definitive proxy statements
24/5/202422:00EDGAR2Form 8-K - Current report
15/5/202414:01PRNUSIntensity Therapeutics, Inc. Announces the Appointment of..
10/5/202422:00EDGAR2Form 8-K - Current report
10/5/202414:01PRNUSIntensity Therapeutics, Inc. and The Swiss Group for..
09/5/202422:13EDGAR2Form 8-K - Current report
09/5/202422:08PRNUSIntensity Therapeutics Reports First Quarter 2024 Financial..
09/5/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/4/202414:01PRNUSIntensity Therapeutics to Participate in the LD Micro..
26/3/202413:01GLOBEPortage Biotech Completes Monetization of Intensity..
14/3/202421:09PRNUSIntensity Therapeutics Reports Full Year 2023 Financial..
14/3/202413:00PRNUSIntensity Therapeutics to Participate in the 36th Annual..
08/3/202400:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202400:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202400:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202414:01PRNUSIntensity Therapeutics to Present at the 2024 BIO CEO &..
Apertura: 2,16 Min: 2,16 Max: 2,33
Chiusura: 2,17

La tua Cronologia

NASDAQ
INTS
Intesity Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci